Celgene

Celgene was a biopharmaceutical company that focused on developing and commercializing therapies for cancer and inflammatory diseases. The company was acquired by Bristol Myers Squibb in 2019 and now operates as part of that organization. UpGuard continuously monitors the security posture of Celgene using open-source, commercial, and proprietary threat intelligence feeds. Our analysis is centered on objective, externally verifiable information.

Celgene Security Rating

X
---
/ 950
Celgene's security rating is based on the analysis of their external attack surface. The higher the rating, the better their security posture. Start a free trial to get a more in-depth risk assessment for Celgene.

Company info

Celgene
Company
Celgene
Employees
Location
Summit, NJ, United States.
CEO
Mark J. Alles
Last updated
Last updated
Industries
Last updated today

Celgene Vendor Risk Report

This vendor risk report is based on UpGuard’s continuous monitoring of Celgene's security posture using open-source, commercial, and proprietary threat intelligence feeds. The results are summarized into a security rating based on the analysis of hundreds of individual checks across five risk categories: website security, email security, phishing & malware, brand & reputation risk, and network security.

Last updated today

Celgene Data Breaches, Cybersecurity Incidents and News

Security incidents, news, and data leaks relating to Celgene.

Security reports related to Celgene

Compare Celgene's security performance with other companies in their industry.
Free instant security score

How secure is your organization?

Request a free cybersecurity report to discover key risks on your website, email, network, and brand.
  • Check icon
    Instant insights you can act on immediately
  • Check icon
    Hundreds of risk factors including email security, SSL, DNS health, open ports and common vulnerabilities
Website Security scan resultsWebsite Security scan rating